| Not Yet Recruiting | JS212 Combination Therapies in Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 2 | 2026-04-15 |
| Not Yet Recruiting | Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumo Advanced Malignant Solid Tumors | Phase 2 | 2026-04-02 |
| Not Yet Recruiting | A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal S Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Phase 2 | 2026-03-23 |
| Not Yet Recruiting | A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer Advanced Lung Cancer | Phase 2 | 2025-12-30 |
| Recruiting | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Ad Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2025-12-24 |
| Recruiting | JS207 Combination Therapy in Triple-negative Breast Cancer Triple-negative Breast Cancer | Phase 2 | 2025-09-17 |
| Recruiting | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma B-cell Non-Hodgkin's Lymphoma | Phase 2 | 2025-08-17 |
| Recruiting | Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Ch Advanced NSCLC | Phase 2 | 2025-07-15 |
| Recruiting | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC Non-small Cell Lung Cancer | Phase 2 | 2025-06-19 |
| Recruiting | A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell L Non-squamous Non-small Cell Lung Cancer | Phase 2 | 2025-05-30 |
| Recruiting | JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2025-05-29 |
| Recruiting | A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemothe Advanced Colorectal Cancer | Phase 2 | 2025-04-23 |
| Not Yet Recruiting | JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC NSCLC | Phase 2 | 2025-04-20 |
| Recruiting | A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS2 Advanced Malignant Solid Tumours | Phase 1 / Phase 2 | 2025-04-11 |
| Recruiting | A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor | Phase 1 | 2025-02-21 |
| Completed | A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector Health Volunteer | Phase 1 | 2024-12-20 |
| Recruiting | Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2024-10-23 |
| Active Not Recruiting | JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small C Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer | Phase 3 | 2024-07-11 |
| Unknown | A Clinical Study of JS005 in Patients With Ankylosing Spondylitis Ankylosing Spondylitis | Phase 2 | 2024-01-12 |
| Recruiting | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2024-01-03 |
| Recruiting | A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patient Hodgkin Lymphoma | Phase 3 | 2023-12-28 |
| Recruiting | Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients Wi Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | 2023-11-15 |
| Active Not Recruiting | The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant T Advanced Malignant Tumor | Phase 1 | 2023-09-26 |
| Unknown | A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401 Hyperlipidemia | Phase 1 | 2023-08-31 |
| Completed | A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adult Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | 2023-08-28 |
| Recruiting | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III St Intrahepatic Cholangiocarcinoma | Phase 3 | 2023-06-19 |
| Completed | A Pharmacokinetic Study of JS002 in Healthy Subjects Health Volunteer | Phase 1 | 2023-05-30 |
| Unknown | A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immu Migraine | Phase 1 | 2023-05-09 |
| Withdrawn | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Primary Condition: Advanced Tumors | Phase 1 | 2023-03-31 |
| Active Not Recruiting | Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 1 | 2023-02-13 |
| Completed | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer Advanced Lung Cancer | Phase 1 / Phase 2 | 2023-02-09 |
| Recruiting | Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipide Primary Hypercholesterolaemia and Mixed Dyslipidemia | Phase 3 | 2023-02-03 |
| Unknown | A Phase I Study Of JS015 in Patients With Advanced Solid Tumors Advanced Solid Cancer | Phase 1 | 2023-02-01 |
| Unknown | A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma Advanced Nasopharyngeal Carcinoma | Phase 1 | 2022-10-21 |
| Terminated | A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined Wit Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer | Phase 1 | 2022-07-28 |
| Unknown | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors Advanced Solid Tumors | Phase 1 | 2022-07-26 |
| Terminated | A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 | 2022-04-28 |
| Terminated | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer Advanced Pancreatic Cancer | Phase 1 | 2022-03-29 |
| Withdrawn | JS001+IMP4297 in Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2022-03-29 |
| Withdrawn | A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies Previously Treated, Advanced, Malignancies | Phase 1 | 2022-03-15 |
| Completed | The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipid Hyperlipemia | Phase 3 | 2022-02-28 |
| Active Not Recruiting | PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer Gastric or Esophagogastric Junction Adenocarcinoma | Phase 3 | 2022-02-10 |
| Terminated | A Study Explore JS001+JS002 in Patients With Advanced Cancer Advanced Cancer | Phase 1 | 2022-02-10 |
| Unknown | Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Non-radiographic Axial Spondyloarthritis | Phase 2 | 2022-01-26 |
| Completed | A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolem Heterozygous Familial Hypercholesterolemia | Phase 3 | 2021-12-31 |
| Completed | A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19 COVID-19 | Phase 1 | 2021-12-16 |
| Unknown | Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Active Ankylosing Spondylitis | Phase 2 | 2021-12-10 |
| Unknown | Clinical Study of JS007 in Patients With Advanced Solid Tumors Patients With Advanced Solid Tumors | Phase 1 | 2021-11-17 |
| Completed | Study of JS004 Combined With Toripalimab for Advanced Lung Cancer Advanced Lung Cancer | Phase 1 / Phase 2 | 2021-08-27 |
| Unknown | Clinical Study of JS201 in Patients With Advanced Malignant Tumors Patients With Advanced Malignant Tumors | Phase 1 | 2021-07-29 |
| Active Not Recruiting | Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally A Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Phase 3 | 2021-05-12 |
| Completed | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | 2021-05-11 |
| Unknown | The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalim Advanced Tumors | Phase 1 | 2021-04-21 |
| Unknown | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. Relapsed or Metastatic Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2021-04-15 |
| Unknown | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors Melanoma, Renal Carcinoma, Urothelial Carcinoma | Phase 1 | 2021-04-12 |
| Unknown | A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Canc Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | 2021-04-06 |
| Completed | Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing Moderate to Severe Psoriasis | Phase 1 / Phase 2 | 2021-01-20 |
| Completed | The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Hyperlipemia | Phase 3 | 2020-12-23 |
| Unknown | A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Loc Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | 2020-11-30 |
| Completed | JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infectio COVID-19 | Phase 1 / Phase 2 | 2020-10-30 |
| Terminated | A Phase I Study of JS108 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2020-10-28 |
| Unknown | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | 2020-10-15 |
| Unknown | A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastat Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | Phase 2 | 2020-09-28 |
| Completed | Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monothe Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 | Phase 3 | 2020-08-20 |
| Completed | To Evaluate the Efficacy and Safety of JS002 in HoFH Patients Hyperlipemia | Phase 2 | 2020-08-17 |
| Completed | A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China Recurrent/Refractory Malignant Lymphoma | Phase 1 | 2020-07-17 |
| Active Not Recruiting | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC Advanced Hepatocellular Carcinoma (HCC) | Phase 3 | 2020-06-29 |
| Unknown | Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Mono COVID-19; and High Infection Risk of SARS-CoV-2 | Phase 1 | 2020-06-05 |
| Completed | Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenu Advanced Solid Tumor | Phase 1 | 2020-04-28 |
| Unknown | A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripali Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | 2020-04-10 |
| Active Not Recruiting | Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC Stage II-III Non-small Cell Lung Cancer | Phase 3 | 2020-04-07 |
| Unknown | Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . Melanoma, Lung Cance, Breast Cancer | — | 2020-02-15 |
| Unknown | Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With P Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005 | Phase 1 | 2020-01-05 |
| Completed | Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer Small Cell Lung Cancer | Phase 3 | 2019-07-23 |
| Completed | A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlip Hyperlipemia | Phase 1 / Phase 2 | 2019-05-23 |
| Unknown | Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TK Non-small Cell Lung Cancer | Phase 3 | 2019-05-06 |
| Terminated | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2019-04-26 |
| Completed | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment- Treatment-naive Advanced Non-small Cell Lung Cancer | Phase 3 | 2019-03-18 |
| Unknown | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection Hepatocellular Carcinoma | Phase 2 / Phase 3 | 2019-03-05 |
| Completed | Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy | Phase 3 | 2019-01-31 |
| Completed | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breas Triple-Negative Breast Cancer | Phase 3 | 2018-12-21 |
| Completed | The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer Recurrent or Metastatic NPC | Phase 3 | 2018-10-18 |
| Completed | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative NSCLC | Phase 2 | 2018-04-09 |
| Completed | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Mon Metastatic Melanoma, Unresectable Melanoma | Phase 3 | 2018-02-02 |
| Completed | A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects Hypercholesterolemia | Phase 1 | 2017-12-11 |
| Completed | The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS NSCLC | Phase 1 | 2017-09-18 |
| Completed | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Malignant Lymphoma | Phase 1 | 2017-07-12 |
| Unknown | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Mucosal Melanoma | Phase 2 | 2017-05-31 |
| Unknown | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcino Bladder Urothelial Carcinoma | Phase 2 | 2017-04-06 |
| Unknown | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer a Kidney Cancer Stage Iv, Advanced Melanoma | Phase 1 | 2017-03-31 |
| Unknown | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Me Advanced Melanoma, Metastatic Melanoma | Phase 2 | 2016-12-28 |
| Unknown | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | 2016-12-01 |
| Unknown | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Lymphoma, Lung Cancer | Phase 1 | 2016-08-01 |
| Completed | Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Brea Breast Cancer | Phase 1 | 2016-07-01 |
| Completed | Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With A Melanoma, Urological Cancer | Phase 1 | 2016-04-01 |
| Completed | Study of JS001 in Participants With Advanced Solid Tumors Solid Tumors | Phase 1 | 2016-03-01 |